These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email corporaterelations@oss-oncology.org for assistance.
Posted on 01/15/2026
View the full publication:
View the Plain Language Summary of the publication
© Johnson & Johnson and its affiliates 2025. 12/25 CP-557697v1
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit or download the resource below to learn more.
Posted on 11/12/2025
The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3
Posted on 11/12/2025
In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.
Posted on 11/6/2025
To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.
Posted on 10/29/2025
MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit for more information.
Posted on 10/29/2025
Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)
Online: Visit
Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.
Pfizer Oncology Together can help healthcare providers by:
Pfizer Oncology Together can help patients by:
Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.
© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024
Posted on 1/16/2025
Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
Posted on 12/28/2024
Posted on 12/02/2024
HCP’s: Use these handouts to help patients understand their Medicare plan:
Posted on 11/20/2024
FDA-Approved Therapy and ICD-10-CM Codes for Desmoid Tumors. Desmoid tumors are rare, locally aggressive soft tissue tumors that are characterized by high rates of initial misdiagnosis.
Posted on 11/13/2024
Changes to Medicare Part D in 2025 will Cap Out-Of-Pocket (OOP) Costs for Patients. Please feel free to review & share this important resource.
Posted on 11/09/2024
Johnson and Johnson’s eighth U.S. Pricing Transparency Report provides key data, analysis and insights that will help advance solutions to create a more sustainable, equitable and innovative healthcare system.
Posted on 11/09/2024
Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
Posted on 11.11.2024
Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
Posted on 10/16/2024
Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.
Posted on 10/16/2024
Posted on 09.26.2024
Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview.
Posted on 08.12.2024
Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.
Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.
Posted on 08.08.2024
The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.
Posted on 07.30.2024
This resource is a guide for pharmacy directors and clinical pharmacists to help clinicians identify the subset of patients with clinical characteristics of advanced polycythemia vera (PV).
Posted on 07.30.2024
This resource is a step-by-step EMR guide for appropriate US population health decision makers or similar entities and their health systems to identify the subset of patients who may have clinical characteristics of advanced polycythemia vera (PV).
Posted on 07.18.2024
This resource is intended for patients looking to:
Posted on 07.18.2024
This resource is intended for eye doctors or oncologists looking to:
Published on: July 15, 2024
Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.
Visit and share this site with your patients.
Published on: July 2, 2024
Coherus is pleased to announce CMS has granted LOQTORZI® (toripalimab-tpzi) a product-specific J Code.
Published on: June 21, 2024
AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
Published on: May 18, 2024
Learn about the importance of early detection and intervention for Breast Cancer-Related Lymphedema (BCRL). Hear expert insights into operationalizing a Lymphedema Surveillance Program, the role of bioimpedance spectroscopy (BIS) for early lymphedema detection, and updates on the latest clinical practice guidelines and research.
Published on: Apr 10, 2024
This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos and Living Beyond Breast Cancer, and is supported by Lilly.
Published on: Mar 24, 2024
This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:
💻 Visiting: https://okt.to/W7ib3U
✉️ Emailing: prp@patientresource.com
📞 Calling: 800-497-7530
